MX342913B - Formas solidas de romidepsina y sus usos. - Google Patents

Formas solidas de romidepsina y sus usos.

Info

Publication number
MX342913B
MX342913B MX2013000446A MX2013000446A MX342913B MX 342913 B MX342913 B MX 342913B MX 2013000446 A MX2013000446 A MX 2013000446A MX 2013000446 A MX2013000446 A MX 2013000446A MX 342913 B MX342913 B MX 342913B
Authority
MX
Mexico
Prior art keywords
solid forms
present disclosure
disclosure provides
compound
romidepsin
Prior art date
Application number
MX2013000446A
Other languages
English (en)
Other versions
MX2013000446A (es
Inventor
Smolenskaya Valeriya
Vrolijk Nicholas
Hanko Jason
Alan Engers David
Hagen Eric
Scott Stults Jeffrey
Harishchandra Naringrekar Vijay
Tzatchev Peykov Viktor
Rodney Foss Willard
Lawrence Darling Neil
Original Assignee
Celgene Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp * filed Critical Celgene Corp *
Publication of MX2013000446A publication Critical patent/MX2013000446A/es
Publication of MX342913B publication Critical patent/MX342913B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La presente invención se refiere a formas sólidas de un compuesto que tiene la fórmula I. En algunas modalidades la presente descripción proporciona formas cristalinas del Compuesto I. En algunas modalidades la presente descripción proporciona formas solvatadas del Compuesto I. En algunas modalidades la presente descripción proporciona formas amorfas del Compuesto I.
MX2013000446A 2010-07-12 2011-07-12 Formas solidas de romidepsina y sus usos. MX342913B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36352210P 2010-07-12 2010-07-12
PCT/US2011/043680 WO2012009336A1 (en) 2010-07-12 2011-07-12 Romidepsin solid forms and uses thereof

Publications (2)

Publication Number Publication Date
MX2013000446A MX2013000446A (es) 2013-05-01
MX342913B true MX342913B (es) 2016-10-19

Family

ID=44514993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000446A MX342913B (es) 2010-07-12 2011-07-12 Formas solidas de romidepsina y sus usos.

Country Status (16)

Country Link
US (5) US20120190817A2 (es)
EP (1) EP2593123B1 (es)
JP (3) JP6049614B2 (es)
KR (1) KR20130092557A (es)
CN (1) CN103108648A (es)
AU (1) AU2011279303B2 (es)
BR (1) BR112013000673A2 (es)
CA (1) CA2804795A1 (es)
ES (1) ES2755909T3 (es)
MX (1) MX342913B (es)
MY (1) MY185130A (es)
NZ (2) NZ706052A (es)
RU (2) RU2016149485A (es)
SG (2) SG10201505475XA (es)
UA (1) UA114074C2 (es)
WO (1) WO2012009336A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674313A1 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Romidepsin-based treatments for cancer
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
MX2014008390A (es) 2012-01-12 2014-09-22 Celgene Corp Formulaciones de romidepsina y sus usos.
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
CN103877010B (zh) * 2012-12-21 2018-06-01 正大天晴药业集团股份有限公司 一种罗米地辛溶液的制备方法
WO2014102731A1 (en) * 2012-12-31 2014-07-03 Leiutis Pharmaceuticals Pvt. Ltd Novel pharmaceutical compositions of romidepsin
ITMI20131856A1 (it) * 2013-11-08 2015-05-09 Gnosis Spa Processo per la preparazione di differenti forme cristalline del s-acetil glutatione e loro utilizzi in formulazioni farmaceutiche e nutraceutiche
CN103861084A (zh) * 2014-02-12 2014-06-18 新乡医学院 Romidepsin在治疗帕金森病中的应用
CN104262456B (zh) * 2014-09-11 2018-01-09 浙江海正药业股份有限公司 一种罗米地辛的新晶型及其制备方法和用途
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CN105801667B (zh) * 2016-03-22 2019-04-09 浙江海正药业股份有限公司 一种制备无定型罗米地辛的方法
RU2019118985A (ru) * 2016-11-22 2020-12-25 Алкалидэкс, Инк. Препараты для лечения устойчивых к действию лидокаина и гипокалиемических состояний
CN109796521B (zh) * 2017-11-17 2022-04-19 上海医药工业研究院 一种罗米地辛醋酸盐晶型及其制备方法
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN111187337B (zh) * 2018-11-15 2023-01-24 上海医药工业研究院 罗米地辛一异丙醇溶剂合物及其晶型、制备方法和应用
EP3902908A4 (en) * 2018-12-24 2024-01-03 Pro Farm Group, Inc. A method for increasing romidepsin production from fermentation broth
CN113813366A (zh) * 2020-06-18 2021-12-21 中国科学院深圳先进技术研究院 罗米地辛在制备预防和治疗抗新冠肺炎新型冠状病毒的药物中的应用
WO2021253338A1 (zh) * 2020-06-18 2021-12-23 中国科学院深圳先进技术研究院 罗米地辛在预防和治疗冠状病毒相关疾病中的应用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US5776905A (en) 1996-08-08 1998-07-07 The Board Of Trustees Of The Leland Stamford Junior University Apoptotic regression of intimal vascular lesions
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
KR20010023449A (ko) 1997-09-02 2001-03-26 나가시마 카쭈시게, 노미야마 아키히코 신규한 환상 테트라펩티드 유도체 및 그 의약 용도
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
MXPA02002505A (es) 1999-09-08 2004-09-10 Sloan Kettering Inst Cancer Nueva clase de agentes de citodiferenciacion e inhibidores de histona desacetilasa y metodos de utilizacion de los mismos.
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
CA2393682C (en) 1999-12-08 2012-01-31 Xcyte Therapies, Inc. Depsipeptide and congeners thereof for use as immunosuppressants
CA2317003A1 (en) 2000-02-28 2001-08-28 Hidenori Nakajima Gene expression potentiator
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
AU2001285042A1 (en) * 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
JP2004508049A (ja) 2000-09-01 2004-03-18 藤沢薬品工業株式会社 Ｆｒ９０１２２８物質の製造法
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
JP2005507231A (ja) 2001-01-10 2005-03-17 アメリカ合衆国 甲状腺新生物の診断および治療におけるヒストン脱アセチル酵素阻害剤
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
ES2310213T3 (es) 2001-05-02 2009-01-01 The Regents Of The University Of California Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
SG157952A1 (en) 2001-05-30 2010-01-29 Univ Michigan Small molecule antagonists of bcl-2 family proteins
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
DK1426054T3 (da) 2001-08-21 2011-12-12 Astellas Pharma Inc Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
US20040259772A1 (en) 2001-08-24 2004-12-23 Antonio Fojo Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
AU2002353891A1 (en) 2001-10-25 2003-05-06 Buck Institute For Age Research Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
WO2003038060A2 (en) 2001-11-01 2003-05-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
AU2002351898A1 (en) 2001-12-21 2003-07-09 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
US20030134423A1 (en) 2002-01-04 2003-07-17 Chu Yong Liang Compounds for delivering substances into cells
EP1482962A4 (en) 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD FOR THE TREATMENT OF TRX-MEDIATED ILLNESSES
WO2003070754A1 (fr) 2002-02-20 2003-08-28 Minoru Yoshida Inhibiteurs d'histone desacetylase et procede de production de ces inhibiteurs
NZ550185A (en) 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
AU2003226014A1 (en) 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
US8673888B2 (en) 2002-04-05 2014-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Depsipeptide for therapy of kidney cancer
WO2003088954A1 (en) 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20040002447A1 (en) 2002-06-04 2004-01-01 Regents Of The University Of California Induction of insulin expression
US20050065596A1 (en) 2002-07-24 2005-03-24 Xufan Tseng Stents capable of controllably releasing histone deacetylase inhibitors
CA2495354A1 (en) 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. An agent for inhibiting articular cartilage extracellular matrix degradation
CA2498210C (en) 2002-09-13 2011-10-18 Virginia Commonwealth University Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
SE0300098D0 (sv) 2003-01-15 2003-01-15 Forskarpatent I Syd Ab Use of cyclin D1 inhibitors
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
EP1595952A4 (en) 2003-02-19 2008-05-21 Astellas Pharma Inc METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
WO2004096289A1 (ja) 2003-04-25 2004-11-11 Fujisawa Pharmaceutical Co 遺伝子導入効率増強剤
US20040213826A1 (en) 2003-04-28 2004-10-28 Marx Steven O. Medical devices and methods for inhibiting proliferation of smooth muscle cells
EP1491188A1 (en) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
DK2238982T3 (da) 2003-06-27 2013-01-28 Astellas Pharma Inc Terapeutisk middel til blødt væv-sarcom
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
EP1663194B1 (en) 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
JP2007504131A (ja) 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
AU2004273910A1 (en) 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
CA2540108A1 (en) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
CA2590257A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
EP1689445B1 (de) 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
WO2005058298A2 (en) 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
ATE437370T1 (de) 2004-02-27 2009-08-15 Us Gov Health & Human Serv Pharmakodynamische tests mit durchflusszytometrie
GB0405349D0 (en) 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
DE602004014723D1 (de) 2004-04-30 2008-08-14 Desitin Arzneimittel Gmbh Histondeacetylase-Inhibitor enthaltende Formulierung zur zweiphasigen Freisetzung
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
WO2005115149A2 (en) 2004-05-20 2005-12-08 Dow Agrosciences Llc Insectidal activity of a cyclic peptide
WO2005117930A2 (en) 2004-06-04 2005-12-15 Sloan-Kettering Institute For Cancer Research Use of thioredoxin measurements for diagnostics and treatments
WO2005123089A2 (en) 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20060018921A1 (en) 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
US7745446B2 (en) 2004-09-06 2010-06-29 Bayer Schering Pharma Aktiengesellschaft Pyrazolo[1,5-c]pyrimidines
JP2008520682A (ja) 2004-11-17 2008-06-19 ザ ユニヴァーシティー オヴ シカゴ ヒストンデアセチラーゼ阻害剤およびその使用方法
US8889742B2 (en) 2004-11-30 2014-11-18 The Trustees Of The University Of Pennsylvania Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury
WO2006060429A2 (en) 2004-12-03 2006-06-08 Novartis Ag Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
US20060128660A1 (en) 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
US7943568B2 (en) 2005-09-30 2011-05-17 The Ohio State University Research Foundation Antitumor agents
JP5319923B2 (ja) * 2005-10-28 2013-10-16 協和発酵バイオ株式会社 濃縮晶析装置および方法
JP2009515524A (ja) 2005-11-10 2009-04-16 アメリカ合衆国 Ａｂｃｂ１多型バリアントスクリーニング、診断及び処置のための物質及び方法
EP1965824A4 (en) 2005-11-18 2011-10-19 Gloucester Pharmaceuticals Inc METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228
CA2649877A1 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US7857804B2 (en) 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
CA2674313A1 (en) 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Romidepsin-based treatments for cancer
JP2010514801A (ja) * 2006-12-29 2010-05-06 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンの精製
CN102276689A (zh) 2011-05-09 2011-12-14 中国药科大学 组蛋白去乙酰化酶抑制剂fk228的化学合成方法及其应用

Also Published As

Publication number Publication date
CA2804795A1 (en) 2012-01-19
JP2013532632A (ja) 2013-08-19
JP6490632B2 (ja) 2019-03-27
NZ605526A (en) 2015-04-24
AU2011279303B2 (en) 2015-07-16
SG187032A1 (en) 2013-02-28
JP6049614B2 (ja) 2016-12-21
NZ706052A (en) 2016-07-29
US20120046442A1 (en) 2012-02-23
SG10201505475XA (en) 2015-09-29
RU2607634C2 (ru) 2017-01-10
RU2016149485A (ru) 2018-10-31
US9518094B2 (en) 2016-12-13
EP2593123A1 (en) 2013-05-22
MY185130A (en) 2021-04-30
JP2019052177A (ja) 2019-04-04
US20150218225A1 (en) 2015-08-06
US20160060300A1 (en) 2016-03-03
BR112013000673A2 (pt) 2016-05-31
UA114074C2 (xx) 2017-04-25
WO2012009336A1 (en) 2012-01-19
US20140256637A1 (en) 2014-09-11
US20120190817A2 (en) 2012-07-26
US9624271B2 (en) 2017-04-18
KR20130092557A (ko) 2013-08-20
RU2013105700A (ru) 2014-08-20
AU2011279303A1 (en) 2013-01-31
JP2017008067A (ja) 2017-01-12
EP2593123B1 (en) 2019-09-04
MX2013000446A (es) 2013-05-01
US8980825B2 (en) 2015-03-17
CN103108648A (zh) 2013-05-15
ES2755909T3 (es) 2020-04-24
US20140336132A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
MX2013000446A (es) Formas solidas de romdepsina y sus usos.
PH12017502300A1 (en) Pesticidal compositions and processes related thereto
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
GB201001075D0 (en) Crystalline forms
EP2519484A4 (en) Bioorganically-augmented high value fertilizer
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX2012008141A (es) Compuestos y metodos.
IN2012DN04748A (es)
EP2415049A4 (en) Negative voltage generation
IN2012DN04414A (es)
IL219243A0 (en) 5-hydroxyprimidine-4-carboxamide derivatives, compositions comprising the same and uses threof
AU2011298391A8 (en) Substituted N-phenethyltriazoloneacetamides and uses thereof
IN2012DN04412A (es)
EP2650330A4 (en) Epdm composition
HK1184739A (en) Romidepsin solid forms and uses thereof
IN2012DN04805A (es)
UA41922U (ru) Применение альтана как вещества с противолучевыми свойствами
UA56041U (ru) 1,3-диметил-7-n-метилбензил-8-гидразиноксантин, который проявляет диуретическое действие
AU2010900738A0 (en) Foliar nutrient compositions
AU2010903712A0 (en) Tutoring Tool
HK1183887A (en) Crystalline ezatiostat hydrochloride ansolvate
IL222981A0 (en) Compound, synthesis, composition and uses thereof
UA27272U (en) Use of yakton as cardioprotector
HK1159121A (en) Crystalline insulin-conjugates
UA42262U (en) 3-METHYL-7-β-HYDROXY-γ-(N-CHLOROPHENOXY)PROPYL-8-METHYLTHIOXANTINE EXHIBITING DIURETIC ACTION

Legal Events

Date Code Title Description
FG Grant or registration